Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 3/20 | 0.38 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | F9 | P00740 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | F12 | P00748 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.35 |
| ▸ | F7 | P08709 | 2/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18637540 | 1.00 | NRP1 (0.38) | NRP1DPP4DPP7F2F9 | |
| SCHEMBL22105960 | 0.94 | NRP1 (0.38) | NRP1DPP4DPP7F2F9 | |
| SCHEMBL17992375 | 0.93 | NRP1 (0.38) | NRP1DPP4DPP7F2F9 | |
| SCHEMBL18637539 | 0.93 | NRP1 (0.38) | NRP1DPP4DPP7F2F9 | |
| SCHEMBL19825876 | 0.85 | NRP1 (0.34) | NRP1F2F9F10F12 | |
| SCHEMBL18637416 | 0.85 | NRP1 (0.34) | NRP1F2F9F10F12 | |
| SCHEMBL24564828 | 0.84 | F2 (0.39) | NRP1DPP4DPP7F2F9 | |
| SCHEMBL19825875 | 0.79 | NRP1 (0.34) | NRP1 | |
| SCHEMBL18637415 | 0.79 | NRP1 (0.34) | NRP1 | |
| SCHEMBL19826065 | 0.79 | NRP1 (0.34) | NRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200188476-A1 | ANTI-MICROBIAL AGENT-POLYMER CONJUGATES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2020-06-18 | — | — | US | disclosed |
| US-10407467-B2 | Polymyxin derivatives and their use in combination therapy together with different antibiotics | NEW PHARMA LICENCE HOLDINGS LIMITED (MT) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188476-A1 | ANTI-MICROBIAL AGENT-POLYMER CONJUGATES AND METHODS OF USE THEREOF | DDOST, MGAM, MSN | NRP1 980/4885DPP4 679/4885DPP7 463/4885 |
| US-10407467-B2 | Polymyxin derivatives and their use in combination therapy together with different antibiotics | MRPS18A, MRPL21, RRP1B | NRP1 851/4885DPP4 1368/4885DPP7 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.